分类: health

  • Global wellness movement elevates sardines as experts call for a reset in metabolic health

    Global wellness movement elevates sardines as experts call for a reset in metabolic health

    In a significant shift within global nutritional guidance, the Medical Wellness Association (MWA) has officially designated 2026 as ‘The Year of the Sardine,’ positioning the humble fish at the forefront of a worldwide metabolic health revolution. This declaration comes amid deteriorating wellness metrics across developed nations, prompting experts to advocate for a fundamental dietary overhaul centered on nutrient-dense, affordable foods.

    MWA President Dr. Christopher Breuleux emphasizes the urgent need to address metabolic dysfunction—a primary driver behind escalating rates of heart disease, diabetes, fatty-liver disease, and certain cancers. The association’s initiative aims to educate consumers globally about the transformative health benefits of nutritionally rich foods, with sardines emerging as an optimal choice.

    James Michael Lafferty, Founding Board Member and Faculty at MWA, clarifies the scientific rationale behind this recommendation: ‘Chronically elevated insulin acts as a storage hormone, prompting the body to accumulate visceral fat around organs when persistently high.’ He identifies conventional low-fat, high-carbohydrate diets as primary contributors to metabolic decline, noting that blood sugar elevation often represents the final stage of decades-long silent damage.

    Sardines offer a powerful nutritional solution to this crisis. They provide high-quality protein and omega-3 fatty acids without carbohydrates, resulting in minimal insulin response. Additionally, they deliver exceptional concentrations of essential vitamins and minerals while ranking among the world’s most cost-effective animal proteins.

    The nutritional value and safety of sardines depend significantly on sourcing and processing methods. Michelle Tiu Lim-Chan, CEO and President of Mega, highlights the importance of origin and freshness: ‘Where the fish comes from and how quickly it’s processed determine its ultimate nutritional value.’ Her company’s ‘catch to can in 12 hours’ protocol, utilizing pristine South Pacific waters, has earned Mega the world’s sole ‘Superfood’ certification for sardines from MWA.

    Market projections indicate substantial growth for the sardine industry, with anticipated acceleration from 7.5% to over 10% annually beginning in 2026. This surge reflects growing scientific validation and consumer awareness about metabolic health management through dietary choices.

    This movement represents more than nutritional trend—it embodies a fundamental rethinking of lifestyle disease management. As Lafferty concludes: ‘Type two diabetes is not a lifelong condition by default. With discipline, it can be reversed through strategic dietary intervention.’ Once considered mere pantry staples, sardines now stand at the intersection of scientific research, economic accessibility, and global wellness advancement.

  • CellSave Arabia qualified by Gilead and Kite to support advanced cell therapy for lymphoma patients

    CellSave Arabia qualified by Gilead and Kite to support advanced cell therapy for lymphoma patients

    In a significant advancement for cancer care in the Middle East, CellSave Arabia has achieved qualification from biotechnology leaders Gilead and Kite to deliver specialized cell storage services for lymphoma treatments across the United Arab Emirates. This strategic collaboration establishes new pathways for patients requiring advanced cellular therapies, particularly CAR T-cell treatments that represent a breakthrough in oncology care.

    As the region’s premier private stem cell laboratory operating under CSG.BIO, CellSave Arabia brings state-of-the-art biobanking capabilities to this partnership. The company maintains internationally recognized accreditations including AABB, FDA, and ISO 2038 certifications, ensuring compliance with global standards for cellular preservation. This infrastructure positions the organization as a critical component in the CAR T-cell treatment process, where secure handling and storage of biological material is paramount.

    Kite, a Gilead subsidiary acquired in 2017, stands as a global pioneer in cell therapy innovation. The company has developed transformative treatments including YESCARTA and TECARTUS, which have demonstrated remarkable efficacy against certain lymphoma variants. To date, more than 32,000 patients worldwide have received Kite’s CAR T-cell therapies through over 555 authorized treatment centers. Within the UAE, the company currently maintains two approved CAR T-cell therapies across four medical indications.

    Alia Abdel-Razeq, Chief Operating Officer of CellSave Arabia, emphasized the patient-centric nature of this collaboration. “Our fundamental mission revolves around placing patients at the core of every innovation we pursue,” she stated. “This partnership enables us to support lymphoma patients with unprecedented levels of precision, safety, and care while maintaining the highest preservation standards for cellular materials.”

    Eslam Khedr, Head of Oncology Regional Headquarters for Gilead and Kite Middle East, highlighted the individualized nature of CAR T therapy. “This approach represents a truly personalized treatment modality with curative intent for patients confronting difficult-to-treat blood cancers,” Khedr explained. “Meeting patient and healthcare professional needs requires robust treatment delivery infrastructure, which we’ve developed through one of the world’s most extensive in-house manufacturing networks.”

    This collaboration underscores the UAE’s emerging role as a regional hub for next-generation biomedical innovation and scientific collaboration. By combining CellSave Arabia’s specialized biobanking expertise with Gilead and Kite’s therapeutic leadership, the partnership aims to streamline treatment pathways, enhance accessibility to advanced cancer therapies, and ultimately improve outcomes for patients battling hematological malignancies across the Middle East.

  • Moderna says FDA refuses its application for new mRNA flu vaccine

    Moderna says FDA refuses its application for new mRNA flu vaccine

    In a significant regulatory development, Moderna announced Tuesday that the U.S. Food and Drug Administration has declined to review the company’s application for an innovative mRNA-based influenza vaccine. The decision represents the latest indication of intensified FDA oversight under Health Secretary Robert F. Kennedy Jr., who has consistently expressed skepticism toward mRNA technology both before and after assuming his current position.

    The FDA issued a ‘refusal-to-file’ letter citing concerns about Moderna’s clinical trial design, which involved 40,000 participants comparing the new vaccine against a standard flu shot. While the study demonstrated superior efficacy in adults aged 50 and older, FDA vaccine director Dr. Vinay Prasad determined the application lacked an ‘adequate and well-controlled trial’ because it didn’t compare the vaccine to ‘the best-available standard of care in the United States at the time of the study.’

    According to Moderna, FDA officials under the Biden administration had provided 2024 guidance indicating that while another brand specifically recommended for seniors would be preferable for participants aged 65 and older, the company’s chosen standard-dose vaccine remained acceptable. Moderna proceeded with the original study design with FDA’s conditional approval.

    The company emphasized that the FDA identified no specific safety or efficacy concerns with their product and noted they had submitted additional data from a separate trial comparing the vaccine against a licensed high-dose shot for elderly patients. Moderna CEO Stephane Bancel stated the decision ‘does not further our shared goal of enhancing America’s leadership in developing innovative medicines.’

    This regulatory action occurs against a backdrop of significant policy shifts under Kennedy’s leadership, including the rollback of COVID-19 shot recommendations, additional warnings for leading mRNA COVID vaccines, and the removal of administration critics from FDA advisory panels. Kennedy previously announced the cancellation of over $500 million in contracts and funding for mRNA vaccine development.

    The refusal marks a departure from decades of FDA practice allowing vaccine manufacturers to update annual flu shots based on immune response data rather than long-term efficacy studies. Prasad’s internal memo last year indicated this streamlined approach would no longer be permitted, prompting criticism from more than a dozen former FDA commissioners.

    Moderna has requested an urgent meeting with the FDA while pursuing regulatory approval for the vaccine in Europe, Canada, and Australia.

  • Dubai introduces region’s first system for 15-minute health inspections for ships

    Dubai introduces region’s first system for 15-minute health inspections for ships

    Dubai has pioneered a groundbreaking maritime health inspection system that dramatically reduces vessel clearance times from two hours to just 15 minutes. The Health Inspection Management Application (HIMA), unveiled at the World Health Expo, represents the region’s first integrated digital solution for combating cross-border health threats through advanced automation and data analytics.

    The innovative system operates through pre-arrival digital integration, where ship tracking technologies provide comprehensive data including the vessel’s last ten ports of call and medical logs before docking. According to Ali Thani Al Mehairi, Consultant at Dubai Health Authority’s Public Health Protection Department, this preemptive data collection enables inspectors to conduct risk assessments prior to physical arrival, transforming the inspection process into a verification procedure rather than a discovery mission.

    HIMA’s intelligent alert system automatically flags vessels with medical incidents exceeding 3% of personnel, prioritizing high-risk ships while expediting clearance for others. The completely digitized workflow eliminates traditional paperwork, allowing ship agents to submit requests and receive approvals through a seamless online platform.

    The phased implementation commenced immediately at Port Rashid and Al Shindagha Port, with comprehensive coverage across all Dubai maritime ports scheduled by late 2026. Authorities confirmed expansion plans for land border crossings by 2027 and are exploring adaptations for air travel security.

    Dr. Alawi Alsheikh-Ali, Director General of DHA, characterized HIMA as “a qualitative leap in the emirate’s public health framework” that reinforces Dubai’s leadership in deploying digital solutions for community safety. The system’s Arabic namesake, meaning “securing your borders,” reflects its core mission of strengthening public health defenses while ensuring uninterrupted commercial operations through smart data utilization and automated risk management.

  • Al Zahra Hospital Dubai introduces advanced photon-counting CT technology

    Al Zahra Hospital Dubai introduces advanced photon-counting CT technology

    Al Zahra Hospital Dubai has achieved a groundbreaking milestone in medical imaging by deploying the NAEOTOM Alpha photon-counting computed tomography system from Siemens Healthineers. This state-of-the-art installation represents the first implementation of this revolutionary technology in the United Arab Emirates, significantly advancing the hospital’s diagnostic capabilities.

    Unlike conventional CT systems that utilize energy-integrating detectors, photon-counting technology operates by detecting and quantifying individual X-ray photons. This innovative approach generates exceptionally high-resolution images with substantially reduced noise interference while simultaneously enabling spectral imaging during every scan. The system’s sophisticated architecture permits superior differentiation between various biological materials including iodine, calcium, and soft tissues within a single imaging session, eliminating the necessity for additional specialized protocols.

    A particularly noteworthy advantage of this cutting-edge technology is its ability to deliver superior image quality while reducing radiation exposure by up to 30% compared to traditional CT systems. This radiation reduction proves especially beneficial for pediatric patients, cardiac imaging cases, and individuals requiring recurrent follow-up examinations. Furthermore, the system incorporates contrast dose optimization features that provide significant advantages for patients with renal impairments or other contraindications to contrast agents.

    In cardiovascular applications, the photon-counting CT demonstrates exceptional capability in imaging challenging coronary cases that previously posed diagnostic difficulties. Patients with extensive coronary calcification, elevated body mass indices, or higher heart rates can now be evaluated with unprecedented clarity. The technology’s enhanced spatial resolution enables more accurate assessment of coronary artery disease and facilitates improved treatment planning strategies.

    The system’s rapid acquisition speed and artificial intelligence-integrated software support make it particularly valuable in neurovascular emergencies. For stroke patients, the technology enables comprehensive evaluation of cerebral vasculature and perfusion within critical timeframes, potentially accelerating life-saving clinical decisions.

    Beyond cardiology and neurology, the technology offers substantial benefits across multiple medical specialties including orthopedics, oncology, and abdominal imaging. The system provides exceptional visualization of complex fractures, orthopedic implants, malignant tumors, and intricate lesions, often accomplishing comprehensive assessment through a single scanning procedure.

    Dr. Amr Aly, Chief Medical Officer at Al Zahra Hospital Dubai, emphasized the strategic importance of this advancement: ‘This technology deployment exemplifies our commitment to integrating world-class diagnostic solutions that enhance both clinical accuracy and patient safety. The photon-counting CT system represents a paradigm shift in medical imaging that will benefit numerous patient populations across our healthcare ecosystem.’

    This technological implementation aligns with Dubai’s broader vision to establish itself as a preeminent global healthcare destination, reinforcing the emirate’s position as a regional center for specialized medical care and cutting-edge technological innovation in the healthcare sector.

  • How Dubai uses VR headsets to help kids relax during treatment

    How Dubai uses VR headsets to help kids relax during treatment

    Dubai Health is spearheading a transformative approach to healthcare through its newly established Centre for Innovation and Technology, deploying cutting-edge technologies to enhance patient experiences and clinical outcomes. The 2,000-square-meter innovation hub serves as the core of this initiative, focusing on converting healthcare challenges into practical, technology-driven solutions.

    A flagship program utilizes virtual reality (VR) headsets to alleviate anxiety and pain in pediatric patients undergoing frequent blood procedures, such as those at the thalassemia center. According to Yacine Hadjiat, Director of the Centre, clinicians reported significant anxiety in young patients during cannulation. The immersive VR experience effectively distracts children, reducing their focus on medical needles and creating a more relaxed treatment environment. This program has already been trialed on over 100 patients and is expanding to emergency and mental health departments across multiple hospitals.

    Beyond VR applications, the innovation center is executing a comprehensive redesign of patient journeys. Through collaboration with clinicians, staff, and medical students, more than 90 improvement projects have been identified to address pain points from registration to waiting times. Enhancements include streamlined digital access via the Dubai Health app, where patients pre-upload information to facilitate seamless clinic visits, and physical redesigns of clinical spaces to reduce stress.

    The center operates through four specialized laboratories focusing on human-centered design, data and artificial intelligence, sensors and wearables, and extended reality technologies.

    Looking toward the future, Dubai Health is advancing a groundbreaking research initiative named Pain Detect, funded by the Dubai Future Foundation’s 2024 RDI grant. This project aims to develop an AI-powered wearable system that objectively measures pain through physiological signals, moving beyond subjective patient descriptions. This technology could revolutionize care for non-communicative patients, including children and intensive care occupants, establishing a new global standard in pain management.

  • Rehab robots in UAE offer new hope for stroke and spinal injury patients

    Rehab robots in UAE offer new hope for stroke and spinal injury patients

    Aster DM Healthcare, a major UAE healthcare provider, is pioneering a revolutionary approach to neurological and pediatric rehabilitation through the deployment of over 21 FDA-approved robotic systems across its facilities this year. These advanced medical technologies represent a significant leap forward in treating stroke survivors, spinal injury patients, and children with developmental conditions.

    The robotic systems, described by Managing Director and Group CEO Alisha Moopen as ‘next level’ technology, work in collaboration with neurosurgeons and physiotherapists to retrain the brain by rebuilding damaged neural connections. ‘There are people who have just given up complete hope after certain injuries,’ Moopen stated. ‘There is a chance that they will be able to walk again.’

    Among the most groundbreaking innovations is the world’s first pediatric rehabilitation robot scheduled for introduction in Dubai later this year. This specialized technology will support children with ADHD and other developmental challenges through integrated brain mapping, virtual reality immersion therapy, and targeted neural stimulation. Moopen emphasized that this advancement ‘will change the way we talk about child behaviors, child psychology and child development issues.’

    Concurrent with its technological expansion, Aster DM Healthcare is significantly growing its physical infrastructure. The group will open two new multi-specialty hospitals in Dubai’s Studio City and Discovery Gardens areas, adding over 250 beds to their current approximately 920-bed UAE capacity. Additionally, plans are underway to expand Aster Hospital in Al Qusais with 122 operational beds.

    Moopen attributed this expansion to demographic shifts rather than increased illness rates. ‘It’s not that people are getting sicker; it’s that people are living longer,’ she explained. ‘When your length of life has increased, the requirement for healthcare increases.’ This longevity trend has created new demand for geriatric care services, with the UAE seeing more retirees choosing to settle in the country.

    Complementing these developments, Aster launched the Thrive system—a comprehensive preventive health assessment that tests for 100 biomarkers including blood health, cardiac function, metabolism, hormones, inflammation, and nutritional status. This proactive health monitoring platform will integrate with major wearable devices and the myAster app, enabling physicians to provide personalized insights and preventive recommendations for long-term wellbeing.

  • Ban on mercury thermometers sparks panic buying and market transformation

    Ban on mercury thermometers sparks panic buying and market transformation

    A nationwide prohibition on mercury thermometer manufacturing has triggered unprecedented market dynamics across China, revealing deep public attachment to the traditional medical device while accelerating the healthcare sector’s digital transformation. The ban, effective January 1, 2026, implemented under China’s commitments to the Minamata Convention on Mercury, has sparked both consumer anxiety and industry innovation.

    Pharmaceutical retailers from Wuhan to Beijing report extraordinary buying surges, with prices escalating from approximately $0.70 to over $4 per unit within days. Pharmacy owner Tan Enping described implementing purchase limits as inventories dwindled: “Even with rationing of two thermometers per customer, our supplies will vanish rapidly due to overwhelming demand.”

    The phenomenon stems from generations of trust in mercury-based thermometry, with many households considering them irreplaceable despite recognized hazards. Public health expert Su Jing from Tsinghua University clarified this represents “an inevitable measure” for environmental and health protection, noting mercury’s documented risks to neurological and renal systems when devices break and release toxic vapor.

    Meanwhile, healthcare institutions have already completed their transition to digital alternatives. Wuhan No. 9 Hospital head nurse Wu Yin confirmed full departmental adoption of electronic thermometers five years ago, highlighting advantages including automated data recording and reduced infection transmission.

    Manufacturers like Yuyue Medical Equipment & Supply Company have substantially pivoted toward electronic devices, with mercury products now constituting a minor segment of their operations. Contemporary alternatives encompass digital oral thermometers and infrared temporal/auricular models employing advanced sensor calibration systems that meet clinical accuracy standards.

    The policy specifically prohibits manufacturing rather than possession or sale of existing inventory, creating an interim period where education about proper mercury cleanup procedures—including ventilation, protective equipment, and hazardous waste disposal—has become a public health priority.

  • Non-medical sale of GLP-1 weight-loss drugs on the rise; UAE expert warns of risks

    Non-medical sale of GLP-1 weight-loss drugs on the rise; UAE expert warns of risks

    The rapid commercialization of GLP-1 weight-loss medications through non-medical channels is raising significant safety concerns among healthcare professionals in the UAE. What began as strictly controlled pharmaceutical treatments have now entered the consumer marketplace through subscription services, wellness clinics, and even home service apps.

    Dr. Ali Hashemi, CEO of metabolic.health (GluCare), emphasizes that the medications themselves aren’t problematic when properly administered. ‘When prescribed appropriately with thorough screening and follow-up, they represent among the most significant advancements in metabolic health we’ve encountered,’ he stated. The danger emerges when these powerful drugs are treated as convenience products rather than serious medical interventions.

    The acceleration of GLP-1 adoption, fueled by social media visibility and dramatic weight-loss results, has created a market ripe for exploitation. These medications are now being marketed through unconventional channels including aesthetic clinics, IV drip services, and online subscription platforms with minimal clinical oversight. Recently, consumer apps primarily known for home cleaning and spa services have begun promoting obesity treatments alongside their常规 services.

    Medical professionals report seeing patients experiencing preventable complications from improperly managed GLP-1 regimens. These aren’t rare medical anomalies but practical management failures: excessively rapid dosage escalation, insufficient education on side-effect management, inadequate screening for contraindications, and absent follow-up care. Consequences include severe nausea, vomiting, dehydration, constipation, fatigue, and associated anxiety from feeling unwell and unsupported.

    Beyond immediate side effects, experts highlight underreported risks such as significant muscle loss. Dr. Hashemi notes that without proper emphasis on protein intake, resistance training, and lean mass preservation, patients may achieve lower numbers on the scale while actually becoming weaker and less healthy.

    Healthcare management specialist Dr. Sami Mohammed Yesuf warns that the primary risk resides not in the medications themselves but in delivery models that fragment care. ‘Obesity is a complex, chronic disease requiring comprehensive management,’ he explained. ‘When GLP-1 therapy is delivered outside proper medical frameworks, critical risks can be overlooked.’

    The commercialization trend risks transforming obesity medicine from a clinical discipline into an add-on service, potentially leading to increased side effects, treatment discontinuation, weight rebound, and eroded public trust. Additional concerns include inconsistent medication sourcing when drugs are supplied outside regulated pharmacy channels.

    Responsible GLP-1 programs, according to experts, must include proper medical screening, clear titration plans, proactive side-effect management, structured follow-up (especially within the first 8-12 weeks), muscle preservation strategies, and long-term maintenance planning. Patients are advised to inquire directly about prescription sources, side-effect management protocols, follow-up frequency, and medication origins before beginning treatment.

    While innovation and improved access are welcomed, medical professionals stress that accountability remains non-negotiable. The current situation presents a critical juncture where clinical discipline must match commercial demand to prevent lasting damage to patient trust and outcomes.

  • UAE’s first road-rail ambulance promises faster access to remote areas

    UAE’s first road-rail ambulance promises faster access to remote areas

    The United Arab Emirates has unveiled a groundbreaking medical response vehicle capable of operating on both roadways and railway tracks, marking a significant advancement in emergency healthcare accessibility for remote desert areas. This innovative ambulance, domestically manufactured by safety solutions provider Naffco, integrates conventional American ambulance specifications with an adaptable rail gear mechanism inspired by locomotive engineering.

    The development coincides with the rapid expansion of the UAE-Saudi railway infrastructure, centrally supported by Etihad Rail’s 900-kilometer network connecting Ghuweifat at the Saudi border to Fujairah on the eastern coast. This strategic alignment enables the specialized ambulances to leverage emerging rail connections for reaching patients in geographically challenging territories where traditional emergency vehicles face operational limitations.

    According to Mohammed Abdul Jabbar, Sales Account Manager at Naffco FZCO, the vehicle represents a fusion of international standards and localized innovation. “We’ve engineered a dual-mode ambulance that transitions seamlessly between road and rail operations,” Jabbar explained during the World Health Expo demonstration. “When approaching railway tracks, the front-mounted rail gear system engages, elevating the tires and converting the vehicle into a track-compatible emergency transport.”

    The technical specifications reveal a comprehensive medical response unit equipped with advanced life support systems including oxygen and vacuum apparatus, DC/AC power outlets, automated external defibrillators, portable ventilators, and comprehensive trauma management kits. The interior configuration features strategically positioned medical cabinets with sliding Plexiglas, multi-access storage compartments, and specialized containment systems for medical waste.

    Notably, the manufacturing process emphasizes local production with selective international component integration. Naffco sources vehicle chassis from Ford and imports the specialized rail mechanism from European suppliers, subsequently engineering the complete emergency response system within UAE facilities.

    This innovation arrives as the Etihad Rail passenger service prepares to connect 11 stations across all seven emirates through phased inaugurations throughout the year. The broader Gulf Cooperation Council railway initiative, targeting full connectivity among six Gulf nations by 2030, further amplifies the potential for cross-border emergency medical cooperation through this pioneering transportation technology.